{"source": "The New York Times", "lead_paragraph": "With activist directors driving up the price, Sanofi-Aventis could find itself shelling out at least $80 a share, or $21.3 billion, to acquire the drug maker ,Genzyme, Bloomberg News reported.", "keywords": [{"rank": "4", "name": "organizations", "value": "Sanofi-Aventis SA"}, {"rank": "3", "name": "organizations", "value": "Genzyme Corp"}, {"rank": "2", "name": "persons", "value": "Icahn, Carl C"}, {"rank": "5", "name": "unknown", "value": "Genzyme Corp|GENZ|NASDAQ"}, {"rank": "1", "name": "type_of_material", "value": "News"}, {"rank": "6", "name": "unknown", "value": "Sanofi-Aventis SA|SNY|NYSE"}], "multimedia": [], "snippet": "With activist directors driving up the price, Sanofi-Aventis could find itself shelling out at least $80 a share, or $21.3 billion, to acquire drugmaker Genzyme, Bloomberg News reported.", "print_page": null, "blog": [], "headline": {"kicker": "DealBook", "main": "Activist Directors Drive Up Price for Genzyme"}, "_id": "4fd39c418eb7c8105d8dbe6a", "web_url": "http://dealbook.nytimes.com/2010/08/02/activist-directors-drive-up-price-for-genzyme/", "slideshow_credits": null, "byline": {"person": [{"organization": "", "rank": 1, "role": "reported"}], "original": "By DEALBOOK"}, "news_desk": null, "word_count": 138, "document_type": "blogpost", "type_of_material": "Blog", "abstract": "With activist directors driving up the price, Sanofi-Aventis could find itself shelling out at least $80 a share, or $21.3 billion, to acquire drugmaker Genzyme, Bloomberg News reported.", "pub_date": "2010-08-02T05:57:31Z", "subsection_name": null, "section_name": "Business Day"}